Nexalin Technology, Inc. Common Stock (NXL) Stock Price

NXLStock

$2.35−94.11%52W

Market Cap$2.46M

P/E—

PEG Ratio—

Div yield—

Beta4.25

NXL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-91.67%

Price vs S&P 500 (4W)-43.64%

VGM Score25.39

Book Value / Share (Quarterly)$0.07

P/TBV (Annual)10.39x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-38.88%

Cash Flow / Share (Quarterly)$-0.28

Price vs S&P 500 (YTD)-97.89%

Gross Margin (TTM)86.16%

Net Profit Margin (TTM)-4139.28%

EPS (TTM)$-0.47

10-Day Avg Trading Volume0.13M

EPS Excl Extra (TTM)$-0.47

Revenue Growth (5Y)4.43%

EPS (Annual)$-0.50

ROI (Annual)-206.94%

Gross Margin (Annual)79.66%

Net Profit Margin (5Y Avg)-3155.40%

Cash / Share (Quarterly)$0.05

Revenue Growth QoQ (YoY)-82.77%

ROA (Last FY)-180.15%

Revenue Growth TTM (YoY)24.23%

EBITD / Share (TTM)$-0.47

Operating Margin (TTM)-4202.44%

Cash Flow / Share (Annual)$-0.30

P/B Ratio1.62x

P/B Ratio (Quarterly)4.47x

Net Income / Employee (Annual)$-1,027,800

EV / Revenue (TTM)6.72x

Net Interest Coverage (TTM)-27.58x

ROA (TTM)-218.44%

EPS Incl Extra (Annual)$-0.50

Current Ratio (Annual)7.25x

Quick Ratio (Quarterly)0.79x

3-Month Avg Trading Volume0.73M

52-Week Price Return-94.11%

Revenue / Employee (TTM)$27,100

Tangible BV / Share (Quarterly)$0.02

P/S Ratio (Annual)8.17x

Asset Turnover (Annual)0.04x

52-Week High$50.70

Operating Margin (5Y Avg)-3252.44%

EPS Excl Extra (Annual)$-0.50

CapEx CAGR (5Y)121.02%

26-Week Price Return-81.77%

Quick Ratio (Annual)6.39x

13-Week Price Return-83.59%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.25x

Enterprise Value$1.46M

Revenue / Share Growth (5Y)-11.24%

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$37,700

Inventory Turnover (Annual)0.22x

Pretax Margin (Annual)-2725.74%

Cash / Share (Annual)$0.26

3-Month Return Std Dev191.10%

Gross Margin (5Y Avg)78.47%

Net Income / Employee (TTM)$-1,123,600

ROE (Last FY)-206.94%

Net Interest Coverage (Annual)-27.97x

EPS Basic Excl Extra (Annual)$-0.50

Receivables Turnover (TTM)2.24x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.47

Receivables Turnover (Annual)15.06x

ROI (TTM)-278.25%

P/S Ratio (TTM)11.35x

Pretax Margin (5Y Avg)-3155.40%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.26

Price vs S&P 500 (52W)-109.64%

Year-to-Date Return-85.96%

5-Day Price Return-30.06%

EPS Normalized (Annual)$-0.50

ROA (5Y Avg)-801.91%

Net Profit Margin (Annual)-2725.74%

Month-to-Date Return-45.09%

Cash Flow / Share (TTM)$-0.63

EBITD / Share (Annual)$-0.51

Operating Margin (Annual)-2781.66%

LT Debt / Equity (Annual)0.00x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.47

P/TBV (Quarterly)16.18x

P/B Ratio (Annual)9.66x

Inventory Turnover (TTM)0.15x

Pretax Margin (TTM)-4139.28%

Book Value / Share (Annual)$0.28

Price vs S&P 500 (13W)-86.27%

Beta4.25x

Revenue / Share (TTM)$0.01

ROE (TTM)-278.25%

52-Week Low$2.10

vGradeD

gGradeD

mGradeF

vgmGradeD

NXL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$3.00	-$3.30	-10.00%(-$0.30)
Q1 2026	May 8, 2026	-$3.00	-$3.30	-10.00%(-$0.30)
Q4 2025	Mar 25, 2026	-$3.60	-$3.90	-8.33%(-$0.30)
Q3 2025	Nov 14, 2025	-$3.60	-$3.90	-8.33%(-$0.30)
Q2 2025	Aug 6, 2025	-$0.14	-$0.10	+28.57%(+$0.04)

NXL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Electromedical Equipment(31)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
NXLNexalin Technology, Inc. Common Stock	D	D	F	11.3x	4.4%	86.2%	-4202.4%	$2.35
MDTMedtronic plc	B	C	B	3.2x	3.8%	65.7%	18.1%	$94.75
ITGRInteger Holdings Corporation	C	C	A	2.3x	11.6%	26.1%	9.7%	$126.70
LIVNLivaNova PLC Ordinary Shares	C	B	B	2.9x	8.2%	68.1%	12.5%	$77.58
TMDXTransMedics Group, Inc. Common Stock	C	B	D	3.7x	88.2%	58.7%	12.2%	$70.78
AXGNAxogen, Inc. Common Stock	F	B	B	8.1x	14.9%	74.6%	-11.8%	$34.62
BLFSBioLife Solutions Inc.	F	C	A	18.4x	14.9%	63.9%	2.9%	$38.61
CNMDCONMED Corporation	B	C	B	1.0x	9.8%	55.8%	8.0%	$46.72
CBLLCeriBell, Inc. Common Stock	F	A	A	9.4x	—	88.9%	-68.6%	$25.04
INMDInMode Ltd. Ordinary Shares	A	D	C	2.2x	12.4%	76.5%	18.5%	$14.16
CVCapsoVision, Inc. Common Stock	F	D	B	25.0x	—	50.9%	-217.1%	$6.53
ELMDElectromed, Inc.	C	B	C	3.1x	15.6%	78.5%	18.8%	$27.42
FOCLEDAP TMS S.A. American Depositary Shares	C	C	D	2.3x	9.4%	47.6%	-40.7%	$4.09
STXSStereotaxis, Inc. Common Stock	D	F	D	3.4x	4.0%	55.6%	-75.7%	$1.01
VANIVivani Medical, Inc. Common Stock (DE)	—	—	C	29.9x	—	36.4%	-1004.7%	$1.12
NRXSNeuraxis, Inc.	F	A	A	18.2x	13.1%	85.5%	-144.5%	$7.70
STEXStreamex Corp. Common Stock	—	C	F	298.3x	—	100.0%	-10384.3%	$0.37
HYPRHyperfine, Inc. Class A Common Stock	C	A	D	4.8x	115.2%	51.4%	-203.3%	$0.75
OMOutset Medical, Inc. Common Stock	A	C	C	0.6x	19.1%	41.8%	-56.1%	$3.94
ECORelectroCore, Inc. Common Stock	C	A	B	1.9x	55.7%	87.5%	-37.6%	$7.85
POCIPrecision Optics Corporation, Inc. Common Stock	C	A	C	1.5x	24.2%	17.2%	-11.1%	$4.32
QTIQT Imaging Holdings, Inc. Common Stock	C	A	D	1.3x	—	40.4%	-56.2%	$2.40
ITOCiTonic Holdings Ltd Class A Ordinary Shares	—	A	C	50.5x	—	60.9%	-1776.4%	$3.84
IRIXIridex Corp	B	D	D	0.3x	7.7%	35.9%	-5.4%	$0.81
NDRAENDRA Life Sciences Inc. Common Stock	D	—	C	19.2x	—	51.4%	-1921.6%	$4.74
NUWENuwellis, Inc. Common Stock	—	D	F	0.2x	2.1%	69.7%	-142.9%	$0.55
EDAPEDAP TMS SA	D	C	C	2.2x	9.4%	46.6%	-37.3%	$3.99
EYESCorgi Data & Surveillance ETF	—	C	C	—	—	—	—	$28.78
FONRFonar Corporation	B	D	B	1.3x	4.0%	40.3%	9.1%	$0.00
MASIMasimo Corporation	D	D	B	6.0x	6.0%	61.7%	19.9%	$0.00
QSIAWQuantum-Si Incorporated Warrant	—	—	F	—	—	—	—	$0.00
TIVCTivic Health Systems, Inc. Common Stock	—	B	F	8.4x	13.2%	-58.1%	-1549.0%	$2.49

About Nexalin Technology, Inc. Common Stock

Nexalin Technology develops bioelectronic neurostimulation devices for treating anxiety and insomnia without medications or psychotherapy. The company's Generation 1 product is a cranial electrotherapy stimulation (CES) device that delivers targeted neural stimulation. As a Class II FDA-cleared device, it represents a non-pharmacological treatment option in the mental health care market.